How to Store PYY: Stability and Handling, Per the Research

What the PYY Stability Literature Actually Covers

When people ask how PYY is stored, two very different questions get mixed together. The first is pharmaceutical stability: how a peptide behaves as a dry powder or a solution in a container over time, at a given temperature. The second is biological stability: how fast the peptide is cleaved by enzymes once it is in plasma or tissue. The published PYY literature is heavily weighted toward the second question. Researchers studying peptide YY have repeatedly focused on how the molecule is truncated and inactivated, and on how analogues can be engineered to resist that process.

That distinction matters for anyone reading storage claims. A statement such as "PYY is unstable" usually traces back to enzymatic degradation studies in blood, not to a vial sitting in a refrigerator. This page states, for each topic, whether the underlying evidence is PYY-specific or drawn from general lyophilized-peptide formulation science. This page is for educational purposes only and is not medical advice; consult a licensed physician for any decision involving a medicine, hormone or investigational compound.

Biological Degradation: The PYY-Specific Evidence

The most directly relevant PYY stability work examines what happens to the molecule in a biological matrix. A 2016 study in the American Journal of Physiology investigated in vivo and in vitro degradation of peptide YY3-36 to the inactive fragment peptide YY3-34 in humans (https://pubmed.ncbi.nlm.nih.gov/26818056/). The naming convention in that work is informative on its own: PYY(3-36) loses C-terminal residues to become PYY(3-34), and the study described the shorter product as inactive (https://pubmed.ncbi.nlm.nih.gov/26818056/). Because the C-terminus of PYY(3-36) is the region that engages the Y2 receptor, C-terminal trimming is the degradation route that structural chemists have concentrated on.

Cross-species work has looked at the same question outside humans. A 2016 Peptides paper reported on the metabolism of peptide YY 3-36 in the Göttingen mini-pig and the rhesus monkey (https://pubmed.ncbi.nlm.nih.gov/26774588/). Studies of this kind are the reason preclinical PYY pharmacology so often reports metabolite profiles alongside parent-peptide measurements rather than parent peptide alone (https://pubmed.ncbi.nlm.nih.gov/26774588/).

Engineering Around Degradation

Because native PYY(3-36) is degraded, several research groups have built modified versions. A 2021 paper in Pharmaceutical Research described the rational development of stable PYY(3-36) peptide Y2 receptor agonists (https://pubmed.ncbi.nlm.nih.gov/34272643/). A 2020 paper in Metabolism reported the generation and characterisation of C-terminally stabilised PYY molecules with potential in vivo NPYR2 activity (https://pubmed.ncbi.nlm.nih.gov/32777442/). A 2017 ACS Omega report characterised a short-length peptide YY analogue with an anorectic effect in mice (https://pubmed.ncbi.nlm.nih.gov/30023658/). The practical reading of that body of work is that "PYY" is not one molecule with one stability profile: native sequence, lipidated, truncated and C-terminally stabilised variants behave differently, and a stability statement about one does not transfer to another (https://pubmed.ncbi.nlm.nih.gov/34272643/).

Physical Stability: Aggregation and Self-Assembly

Chemical degradation is only half of peptide stability; the other half is physical behaviour in solution. A 2018 Bioconjugate Chemistry study examined the effect of lipidation on the self-assembly of the gut-derived peptide hormone PYY(3-36) (https://pubmed.ncbi.nlm.nih.gov/29856926/). Self-assembly is the umbrella term for peptide molecules associating into larger structures, and the study's framing — that a chemical modification changed that behaviour — illustrates why formulation scientists treat concentration, solvent and excipients as stability variables rather than neutral details (https://pubmed.ncbi.nlm.nih.gov/29856926/).

This is the one PYY-specific thread that speaks directly to what happens inside a container rather than inside a bloodstream. It does not, however, provide shelf-life numbers, storage temperatures or expiry dates for any particular product (https://pubmed.ncbi.nlm.nih.gov/29856926/).

Laboratory Handling: What Analytical Studies Imply

Pre-analytical handling is a storage question that measurement scientists confront constantly. A 2022 Clinical Chemistry paper described a multiplexed assay to quantify the PP-fold family of peptides in human plasma using microflow liquid chromatography–tandem mass spectrometry (https://pubmed.ncbi.nlm.nih.gov/35015868/). PYY belongs to that PP-fold family, and the existence of dedicated mass-spectrometry methods for it reflects a recurring analytical problem: distinguishing intact peptide from its truncated forms requires a method that can resolve them (https://pubmed.ncbi.nlm.nih.gov/35015868/). That analytical requirement is consistent with human degradation work showing conversion of PYY(3-36) to PYY(3-34) (https://pubmed.ncbi.nlm.nih.gov/26818056/).

Clinical studies that measure PYY alongside other gut signals depend on those handling protocols. For example, a 2023 Nutrients study reported that reduction of plasma branched-chain amino acids after Roux-en-Y gastric bypass was primarily mediated by FGF21 (https://pubmed.ncbi.nlm.nih.gov/37049555/), and a 2015 Proceedings of the Nutrition Society review discussed gut microbiota and energy balance in obesity (https://pubmed.ncbi.nlm.nih.gov/25518735/). Plasma-based endpoints of that kind rest on sample collection and storage conditions being controlled before analysis (https://pubmed.ncbi.nlm.nih.gov/35015868/).

Refrigeration: Lyophilized Versus Reconstituted

No study in the verified citation set for this page tested refrigerated shelf life of lyophilized PYY powder or of a reconstituted PYY solution. What follows is therefore general lyophilized-peptide formulation science, described here as background, and not as a PYY-specific finding.

• Dry (lyophilized) state. Freeze-drying removes most water, and water is a participant in the main chemical degradation routes for peptides — hydrolysis, deamidation and related reactions. In general peptide formulation practice, the dry state is treated as the more stable state, which is why many research peptides are supplied as lyophilized powder rather than solution.
• Reconstituted state. Once a peptide is in aqueous solution, degradation chemistry and physical association both become possible, and formulation variables such as pH, buffer, concentration and the presence of a preservative become relevant. For PYY(3-36) specifically, lipidation was reported to change self-assembly behaviour in solution (https://pubmed.ncbi.nlm.nih.gov/29856926/).
• Product labelling governs. For any licensed or supplied material, the manufacturer's own stability data — not extrapolation from a different peptide — defines the storage condition and in-use period on the label.

Shelf Life, Expiry and Room Temperature

Expiry dating is a regulatory and manufacturing construct: it reflects real-time and accelerated stability testing performed on a specific formulation, in a specific container closure, under defined temperature and humidity conditions. That testing is product-specific. Nothing in the PYY papers cited on this page assigned a shelf life, an expiry interval or a room-temperature excursion limit to PYY in any container (https://pubmed.ncbi.nlm.nih.gov/34272643/). Claims that circulate about "X days at room temperature" for research peptides generally come from vendor material or from other peptides entirely, and the distinction is worth checking before any such figure is repeated.

General formulation principles that apply broadly to lyophilized peptides — again, not PYY-specific findings — include that degradation rates tend to increase with temperature, that light and oxygen exposure are handled through container and closure choice, and that residual moisture content in a lyophilized cake is a monitored parameter during stability testing.

Freezing and Freeze-Thaw

Freezing is often assumed to be universally protective. In general peptide science, the picture is more nuanced: freezing slows chemical reactions, but freeze-thaw cycling introduces mechanical and interfacial stresses that can promote aggregation in some proteins and peptides. For PYY(3-36), the published work relevant to association behaviour is the lipidation and self-assembly study (https://pubmed.ncbi.nlm.nih.gov/29856926/), which addressed molecular design rather than freeze-thaw protocols. Analytical laboratories handling plasma samples containing PP-fold peptides define their own freeze-thaw limits during method validation (https://pubmed.ncbi.nlm.nih.gov/35015868/).

Signs of Degradation: What Studies and Formulation Science Describe

Visual inspection is a blunt instrument. Chemical truncation of the kind reported for PYY(3-36) in humans — conversion to PYY(3-34) — is invisible to the eye and was detected analytically, not visually (https://pubmed.ncbi.nlm.nih.gov/26818056/). In general pharmaceutical practice, visible changes such as cloudiness, particulates, discoloration, a collapsed or shrunken lyophilized cake, or material that fails to dissolve are treated as signals of a problem, but their absence is not evidence of chemical integrity. Confirming identity and purity requires chromatographic or mass-spectrometric methods of the type described for PP-fold peptides in human plasma (https://pubmed.ncbi.nlm.nih.gov/35015868/).

Evidence Map: Compound-Specific Versus General

Why Formulation Work Continues

Interest in stabilising PYY has not slowed. A 2025 Journal of Nanobiotechnology paper described an adeno-associated virus gene therapy strategy for anti-obesity treatment using nanocarrier-based delivery systems (https://pubmed.ncbi.nlm.nih.gov/40685368/), and a 2026 paper in the American Journal of Physiology — Endocrinology and Metabolism reported that PYY(3-36) potentiated semaglutide-mediated mitochondrial modulation in MASLD (https://pubmed.ncbi.nlm.nih.gov/42526426/). PYY has also appeared in biomarker work, including a 2025 Archives of Gerontology and Geriatrics study of novel plasma protein biomarkers in a time-dependent predictive model for Alzheimer's disease (https://pubmed.ncbi.nlm.nih.gov/39427525/). Delivery engineering and plasma biomarker panels both exist partly because the native peptide is short-lived in circulation, as the human degradation study described (https://pubmed.ncbi.nlm.nih.gov/26818056/).

Reading Storage Claims Critically

1. Check which molecule is meant. PYY(1-36), PYY(3-36), lipidated analogues and C-terminally stabilised variants are chemically distinct, and researchers built the latter precisely because the native forms were degraded (https://pubmed.ncbi.nlm.nih.gov/32777442/).
2. Check whether a claim is about a vial or about blood. Human degradation findings describe plasma behaviour, not container shelf life (https://pubmed.ncbi.nlm.nih.gov/26818056/).
3. Check whether numbers come from the product. Expiry dates and in-use periods derive from formulation-specific stability programmes, not from pharmacology papers such as the mini-pig and rhesus monkey metabolism study (https://pubmed.ncbi.nlm.nih.gov/26774588/).
4. Check the matrix. Solution composition can change association behaviour, as the lipidation and self-assembly work illustrated (https://pubmed.ncbi.nlm.nih.gov/29856926/).

Research-use-only materials are not approved medicines, carry no clinical labelling, and are not subject to the same stability documentation requirements as licensed products. Questions about any specific material belong with the supplier's certificate of analysis and with a licensed clinician or qualified laboratory professional.

References

• In vivo and in vitro degradation of peptide YY3-36 to inactive peptide YY3-34 in humans (American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 2016)
• Metabolism of peptide YY 3-36 in Göttingen mini-pig and rhesus monkey (Peptides, 2016)
• The Effect of Lipidation on the Self-Assembly of the Gut-Derived Peptide Hormone PYY(3-36) (Bioconjugate Chemistry, 2018)
• Rational Development of Stable PYY(3-36) Peptide Y(2) Receptor Agonists (Pharmaceutical Research, 2021)
• Generation and characterisation of C-terminally stabilised PYY molecules with potential in vivo NPYR2 activity (Metabolism: Clinical and Experimental, 2020)
• A Short-Length Peptide YY Analogue with Anorectic Effect in Mice (ACS Omega, 2017)
• Multiplexed Assay to Quantify the PP-Fold Family of Peptides in Human Plasma Using Microflow Liquid Chromatography-Tandem Mass Spectrometry (Clinical Chemistry, 2022)
• Reduction of Plasma BCAAs following Roux-en-Y Gastric Bypass Surgery Is Primarily Mediated by FGF21 (Nutrients, 2023)
• Gut microbiota and energy balance: role in obesity (The Proceedings of the Nutrition Society, 2015)
• An adeno-associated virus gene therapy strategy for anti-obesity treatment by nanocarrier-based delivery systems (Journal of Nanobiotechnology, 2025)
• PYY(3-36) potentiates semaglutide-mediated mitochondrial modulation in MASLD (American Journal of Physiology. Endocrinology and Metabolism, 2026)
• Novel plasma protein biomarkers: A time-dependent predictive model for Alzheimer's disease (Archives of Gerontology and Geriatrics, 2025)